Scarica l'app Stockscreener
27.27
0.69%
-0.19
Precedente Chiudi:
$27.46
Aprire:
$27.52
Volume 24 ore:
1.18M
Relative Volume:
0.99
Capitalizzazione di mercato:
$1.59B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
2.4005
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-1.66%
1M Prestazione:
-37.50%
6M Prestazione:
-20.96%
1 anno Prestazione:
-28.56%
Intervallo 1D:
$26.78
$27.66
Intervallo di 1 settimana:
$26.78
$28.61
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.27 | 1.60B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Frazier Life Sciences Management L.P. Increases Stock Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by Bellevue Group AG - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Position Boosted by Boothbay Fund Management LLC - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Agios Pharmaceuticals, Inc. (AGIO) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
Is Agios Pharmaceuticals Inc 8AP a good long term investmentSell Signals and Alerts & Learn From the Strategies of Institutions - earlytimes.in
Agios Pharmaceuticals, Inc. (AGIO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - ACCESS Newswire
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date - The Globe and Mail
Agios Pharma stock awaits FDA decision on Pyrukynd as PDUFA date passes - Investing.com Canada
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Marshall Wace LLP Purchases 163,796 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals' Supplemental NDA for Mitapivat to Treat Thalassemia Still Under FDA Review - marketscreener.com
Agios shares slide after FDA misses decision deadline on mitapivat application - MSN
Agios Pharmaceuticals (AGIO) Awaits FDA Decision on Mitapivat Ap - GuruFocus
Agios Pharmaceuticals says FDA has not issued decision on Agios' sNDA for mitapivat - marketscreener.com
FDA delays decision on Agios’ thalassemia drug application By Investing.com - Investing.com Canada
Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing - TradingView — Track All Markets
Agios Pharmaceuticals Provides Update on FDA Review Status for Supplemental New Drug Application of Mitapivat for Thalassemia - Quiver Quantitative
Agios stock falls after FDA delays decision on thalassemia drug By Investing.com - Investing.com UK
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - The Manila Times
Agios (Nasdaq: AGIO) says FDA mitapivat thalassemia sNDA still under review after Dec. 7 PDUFA goal date - Stock Titan
(AGIO) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom - Finimize
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC (AGIO) Investigation: Bronstei - The National Law Review
How Agios Pharmaceuticals Inc. (8AP) stock trades pre earningsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock stays on buy listsPortfolio Update Report & Growth Oriented Trading Recommendations - Newser
How analysts rate Agios Pharmaceuticals Inc. stock todayPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock appears on watchlists2025 Historical Comparison & Real-Time Stock Entry Alerts - Newser
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat - Sahm
Europe Autoimmune Hemolytic Anemia Therapeutics Market to hit - openPR.com
How cyclical is Agios Pharmaceuticals Inc. (8AP) stock compared to rivalsJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateWeekly Trading Summary & Weekly Return Optimization Plans - Newser
Published on: 2025-12-03 01:52:18 - Newser
FDA’s docket holds 16 more PDUFA dates by year-end - BioCentury
Prudential Financial Inc. Lowers Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. (8AP) stock gains from tech spending2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - MSN
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-02 00:03:25 - Newser
Is Agios Pharmaceuticals Inc a good long term investmentPortfolio Risk Assessment & Minimal Capital Trading Tips - earlytimes.in
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Chart Watch & Verified Stock Trade Ideas - BỘ NỘI VỤ
How Agios Pharmaceuticals Inc. stock valuations compare to rivals2025 Biggest Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results - Sahm
Envestnet Asset Management Inc. Reduces Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Aug Intraday: How strong is Agios Pharmaceuticals Inc. stock balance sheet2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Aristocrats List & Trusted Financial Advisors at No Cost - earlytimes.in
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):